To the full analysis
Buyback calculator for Altimmune
Altimmune stock: key metrics
ALTAltimmune had an operating margin of −230,461% and a return on invested capital (ROIC) of −37.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | 65.1% | 55.0% |
| 2007 | 100.0% | −112.7% | −92.8% |
| 2008 | 100.0% | −107.1% | −110.6% |
| 2009 | 100.0% | −94.3% | −117.2% |
| 2010 | 100.0% | −112.2% | −166.0% |
| 2011 | 100.0% | −48.3% | −15.6% |
| 2012 | 100.0% | −24.9% | −19.5% |
| 2013 | 100.0% | −60.5% | −65.4% |
| 2014 | 58.1% | −100.0% | −97.7% |
| 2015 | 52.4% | −32.0% | −32.3% |
| 2016 | −38.1% | −215.4% | 3,706.4% |
| 2017 | −44,249.4% | −125,401.2% | −111,860.3% |
| 2018 | −78.7% | −414.6% | −379.2% |
| 2019 | 100.0% | −370.0% | −353.7% |
| 2020 | −309.4% | −669.5% | −599.2% |
| 2021 | 100.0% | −2,197.6% | −2,201.6% |
| 2022 | no data | no data | no data |
| 2023 | 100.0% | −22,518.5% | −20,762.2% |
| 2024 | 100.0% | −515,860.0% | −475,295.0% |
| 2025 | 100.0% | −230,461.0% | −214,861.0% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 1.8% | 1.8% | 1.4% |
| 2007 | −33.5% | −40.2% | −20.4% |
| 2008 | −100.0% | −56.0% | −64.6% |
| 2009 | −100.0% | −70.2% | −94.8% |
| 2010 | −100.0% | −89.4% | −100.0% |
| 2011 | −24.0% | −47.2% | −16.7% |
| 2012 | −42.1% | −27.9% | −21.6% |
| 2013 | −100.0% | −57.5% | −68.4% |
| 2014 | −54.5% | −49.4% | −45.3% |
| 2015 | −20.7% | −14.2% | −17.3% |
| 2016 | 200.0% | −56.0% | 86.3% |
| 2017 | −95.4% | no data | −73.7% |
| 2018 | −81.1% | −61.8% | −71.5% |
| 2019 | −45.1% | −33.8% | −38.0% |
| 2020 | −21.7% | −30.6% | −20.0% |
| 2021 | −48.8% | −35.3% | −44.4% |
| 2022 | −45.7% | −35.5% | −40.9% |
| 2023 | −45.6% | −39.0% | −42.0% |
| 2024 | −77.0% | −49.8% | −68.2% |
| 2025 | −39.2% | −37.9% | −31.5% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2018)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.